Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The side-effect profile of GM-CSF.

A C Stern1, T C Jones

  • 1Sandoz Pharma AG, Basel, Switzerland.

Infection
|January 1, 1992
PubMed
Summary

Granulocyte-macrophage colony-stimulating factor (GM-CSF) effectively treats neutropenia. Current dosing strategies minimize side effects, improving the benefit-risk ratio for patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular detection of cosaviruses in a patient with acute flaccid paralysis and in sewage samples in Germany.

Virus research·2021
Same author

Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) Reduces Pancytopenia After Rescue Therapy in a Patient with Hodgkin's Lymphoma.

Leukemia & lymphoma·2016
Same author

Antibody landscapes after influenza virus infection or vaccination.

Science (New York, N.Y.)·2014
Same author

Analogous pathologic patterns in different animal species; an approach to the study of obscure lesions.

Bulletin. International Association of Medical Museums·2014
Same author

Pathologic and clinical features of canine testicular tumors.

Bulletin. International Association of Medical Museums·2014
Same author

Experimental and theoretical studies of the interaction of gas phase nitric acid and water with a self-assembled monolayer.

Physical chemistry chemical physics : PCCP·2012

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Background:

  • Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic growth factor with diverse clinical applications.
  • GM-CSF has demonstrated efficacy in preventing and reversing neutropenia across various patient populations.

Purpose of the Study:

  • To review the clinical efficacy and safety profile of GM-CSF.
  • To define appropriate dosing, routes, and schedules for GM-CSF administration.
  • To identify patient groups requiring careful monitoring during GM-CSF therapy.

Main Methods:

  • Review of clinical trial data and established therapeutic guidelines for GM-CSF.
  • Analysis of dose-related adverse effects and specific patient risk factors.
  • Evaluation of administration routes (intravenous vs. subcutaneous) and their impact on safety.

Main Results:

  • GM-CSF effectively prevents or reverses neutropenia.
  • Adverse effects are dose-dependent, with mild-to-moderate reactions (fever, myalgia, rash) common at doses of 5-10 micrograms/kg/day.
  • High doses or specific administration methods (e.g., IV bolus) are associated with severe adverse events like pericarditis, thrombosis, and first-dose reactions.

Conclusions:

  • Appropriate dosing (5-10 micrograms/kg/day) and administration routes (subcutaneous or 4-6h IV infusion) significantly improve the GM-CSF benefit:risk ratio.
  • Careful monitoring is crucial for specific patient groups, including those with myelodysplastic syndrome, acute myeloid leukemia, or inflammatory/autoimmune conditions.
  • Current therapeutic strategies allow for safe and effective use of GM-CSF in clinical practice.

Related Experiment Videos